Completed PHASE1 INTERVENTIONAL 1-arm NCT03117101

Study of the AL3810 in the Treatment of Advanced Solid Tumor

An Open-label, Dose-finding Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, Pharmacodynamics of the Dual -VEGFR-FGFR Tyrosine Kinase Inhibitor, AL3810, Givenorally as Single Agent to Patients With Advanced Solid Tumours

Sponsor: Haihe Biopharma Co., Ltd.

Conditions Advanced Solid Tumors

Interventions Lucitanib

Updated 7 times since 2017 Last updated: Apr 14, 2017 Started: Mar 31, 2014 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03117101, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by Haihe Biopharma Co., Ltd., it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

Methodology: This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study with a traditional 3+3 design, conducted in Chinese patients with advanced solid tumours without an established therapeutic alternative.This study was performed in strict accordance with Good Clinical Practice including the archiving of essential documents.

Methodology:

This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study with a traditional 3+3 design, conducted in Chinese patients with advanced solid tumours without an established therapeutic alternative.This study was performed in strict accordance with Good Clinical Practice including the archiving of essential documents.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Oct 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Data source: Haihe Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China